Latest Neuroscience News

Cogstate Ltd reports a near doubling in sales contracts for the first half of 2026 but warns of timing-related revenue deferrals that will temper short-term earnings. Despite this, management remains optimistic about medium- and long-term growth prospects.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

Compumedics has landed a $4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, pushing total MEG sales in China to $25 million and reinforcing its leadership in the Asian neuro-imaging market.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

BlinkLab Limited has completed its U.S. pilot study for the Dx 1 smartphone-based autism diagnostic device, demonstrating strong accuracy and securing FDA alignment for its pivotal trial. The results mark a significant step toward transforming early neurodevelopmental diagnostics.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Cogstate Ltd has reported a strong FY25 with 22% revenue growth and a near doubling of profit before tax, declaring its first fully franked dividend and preparing to launch its inaugural AI-powered product in FY26.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Cogstate Ltd has upgraded its FY25 financial guidance, projecting a 20-24% revenue increase and nearly doubling profit before tax compared to last year.

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.